High incidence of atrial fibrillation in patients treated with ibrutinib
High incidence of atrial fibrillation in patients treated with ibrutinib
About this item
Full title
Author / Creator
Baptiste, Florian , Cautela, Jennifer , Ancedy, Yan , Resseguier, Noémie , Aurran, Thérèse , Farnault, Laure , Escudier, Marion , Ammar, Chloé , Gaubert, Mélanie , Dolladille, Charles , Barraud, Jeremie , Peyrol, Michael , Cohen, Ariel , Paganelli, Franck , Alexandre, Joachim , Ederhy, Stephane and Thuny, Franck
Publisher
England: British Cardiovascular Society
Journal title
Language
English
Formats
Publication information
Publisher
England: British Cardiovascular Society
Subjects
More information
Scope and Contents
Contents
ObjectiveAtrial fibrillation (AF) is one of the most common side effects of ibrutinib, a drug that has dramatically improved the prognosis of chronic B-cell malignancies such as chronic lymphocytic leukaemia (CLL). The true incidence of ibrutinib-related AF (IRAF) is not well known and its therapeutic management poses unique challenges especially d...
Alternative Titles
Full title
High incidence of atrial fibrillation in patients treated with ibrutinib
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e141364c960c483e884ff8da784b3ca4
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e141364c960c483e884ff8da784b3ca4
Other Identifiers
ISSN
2053-3624,2398-595X
E-ISSN
2053-3624
DOI
10.1136/openhrt-2019-001049
